New Delhi : The National Pharmaceutical Pricing Authority (NPPA) has sought the industry to furnish the Price To Retailer (PTR) and Moving Annual Turnover (MAT) of a total of 139 formulations as part of fixing the ceiling prices of these scheduled formulations under the revised Schedule I of the Drugs (Prices Control) Order (DPCO), 2013.

The formulations for which the details were sought include abacavir tablet 60 mg, combination of abacavir 60 mg and lamivudine 30 mg, various strengths of acetylsalicylic acid, amikacin injection, activated charcoal, amoxicillin, combinations of artesunate and sulfadoxine pyrimethamine, barium sulphate, bendamustine hydrochloride, benzylpenicillin powder for injection, budesonide nasal spray, calcium foliage injection, cefadroxil tablet, cefazolin powder for injection, chlorhexidine solution 5%, clarithromycin tablet and capsules, among others.

Request has been made to all the concerned manufacturers/marketing companies to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of July, 2022 in a given format, said NPPA.

The information has been sought to be furnished positively within seven working days from the issue of the office memorandum issued by the Authority in this regard, it said.

The manufacturers or marketing companies should submit the details including the name of the formulation, brand name, composition and strength, dosage and specification, PTF for July, 2022 and MAT for July, 2022. The Authority clarified that the MAT sales, excluding taxes, has to be submitted for July, 2022, which is the total sales during August, 2021 to July, 2022.

The request has been made to various apex pharma associations including the Indian Drugs Manufacturers’ Association (IDMA), Indian Pharmaceutical Alliance (IPA), the Organisation of Pharmaceutical Producers of India (OPPI), Federation of Pharma Entrepreneurs (FOPE), Federation of Lydian Chambers of Commerce and Industry (FICCI) and Associated Chamber of Commerce (ASSOCHAM).

The NPPA is in the process of fixing the ceiling prices of the formulations listed in the Schedule I of the DPCO, 2013, after it has revised the Schedule replacing the National List of Essential Medicines (NLEM), 2015 with the latest NLEM, 2022. It has fixed ceiling prices of over 650 formulations so far, as part of this exercise.

The Authority has earlier said that the number of formulations covered in revised Schedule I include 954 formulations in 388 medicines, with 56 newly added drug formulations. The formulations continued from NLEM, 2015, are around 763 and total unique formulations for which ceiling prices are to be fixed are around 819. However, in view of the expansions to the revised Schedule 1 and others, the number of formulations may increase beyond 954 formulations to around 1000 formulations.

As per the provisions of the DPCO, 2013, the ceiling prices for the medicines in the Schedule I has to be fixed within 60 days from the notification of the Schedule.

While the general practice is that the ceiling prices are fixed by considering the market-based data for fixing the ceiling price of schedule formulation due to revision in the First Schedule shall be the data available for the month ending immediately before six months of notification of revision in the first schedule, the Authority used the data from July, 2022, paying heed to the representations of the industry associations.